NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.)

NTLAのニュース

   Intellia wins Outperform rating at Credit Suisse on ATTR potential  2022/04/28 17:24:27 Seeking Alpha
Credit Suisse has initiated its coverage on gene editing company, Intellia Therapeutics (NTLA) with an Outperform recommendation, arguing that the clinical-stage biotech has…
   4 Analysts Have This to Say About Intellia Therapeutics  2022/04/28 13:15:08 Benzinga
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ: NTLA ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 1 0 0 0 These 4 analysts have an average price target of $128.25 versus the current price of Intellia Therapeutics at $49.34, implying upside. Below is a summary of how these 4 analysts rated Intellia Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the … Full story available on Benzinga.com
   Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates  2022/04/28 11:30:00 GlobeNewswire
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET.
   Intellia Therapeutics Inc. (NASDAQ: NTLA): The Stock To Invest In Over The Next Few Months  2022/04/13 13:00:00 Marketing Sentinel
In the last trading session, 1.25 million Intellia Therapeutics Inc. (NASDAQ:NTLA) shares changed hands as the company’s beta touched 2.02. With the company’s per share price at $61.35 changed hands at -$0.32 or -0.52% during last session, the market valuation stood at $4.80B. NTLA’s last price was a discount, traded about -230.45% off its 52-week … Intellia Therapeutics Inc. (NASDAQ: NTLA): The Stock To Invest In Over The Next Few Months Read More »
   Warning: NTLA is at high risk of performing badly  2022/03/29 08:44:05 Seeking Alpha
   Intellia Therapeutics (NASDAQ:NTLA) Announces Earnings Results  2021/11/07 19:14:41 Dakota Financial News
Intellia Therapeutics (NASDAQ:NTLA) released its earnings results on Thursday. The company reported ($0.97) EPS for the quarter, missing analysts consensus estimates of ($0.85) by ($0.12), MarketWatch Earnings reports. Intellia Therapeutics had a negative return on equity of 39.01% and a negative net margin of 442.58%. The business had revenue of $7.20 million for the quarter, []
   Metropolitan Life Insurance Co NY Buys 17,429 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)  2021/11/07 16:30:43 Transcript Daily
Metropolitan Life Insurance Co NY raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 116,193.3% in the second quarter, Holdings Channel reports. The fund owned 17,444 shares of the companys stock after purchasing an additional 17,429 shares during the quarter. Metropolitan Life Insurance Co NYs holdings in Intellia Therapeutics were worth $2,824,000 at the end []
   Robertson Stephens Wealth Management LLC Invests $323,000 in Intellia Therapeutics, Inc. (NASDAQ:NTLA)  2021/11/07 15:52:41 Dakota Financial News
Robertson Stephens Wealth Management LLC acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,000 shares of the companys stock, valued at approximately $323,000. Several other institutional investors also recently made []
   Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $145.00 by Analysts at Oppenheimer  2021/11/07 14:12:47 Transcript Daily
Intellia Therapeutics (NASDAQ:NTLA) had its price objective decreased by equities research analysts at Oppenheimer from $160.00 to $145.00 in a report issued on Friday, PriceTargets.com reports. The brokerage presently has a market perform rating on the stock. Oppenheimers target price indicates a potential upside of 7.03% from the stocks previous close. NTLA has been the []
   Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results  2021/11/07 02:50:42 Transcript Daily
Intellia Therapeutics (NASDAQ:NTLA) issued its earnings results on Thursday. The company reported ($0.97) earnings per share for the quarter, missing analysts consensus estimates of ($0.85) by ($0.12), MarketWatch Earnings reports. The company had revenue of $7.20 million during the quarter, compared to analyst estimates of $8.66 million. Intellia Therapeutics had a negative net margin of []
   Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/05/27 16:05:12 Investing.com
Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics
   Intellia Therapeutics Inc Shares Close the Day 10.1% Higher - Daily Wrap  2021/05/11 22:30:00 Kwhen Finance
Intellia Therapeutics Inc (NTLA) shares closed today 10.1% higher than it did at the end of yesterday. The stock is currently up 23.2% year-to-date, up 279.6% over the past 12 months, and up 186.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Shares traded as high as $68.82 and as low as $56.47 this week.Shares closed 3e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 11.0% higher than the 10-day average and 18.9% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -199.8% The company's stock price performance over the past 12 months beats the peer average by -3135.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

calendar